

GOVERNMENT OF INDIA
MINISTRY OF COMMERCE & INDUSTRY
(DEPARTMENT OF COMMERCE)

LOK SABHA
UNSTARRED QUESTION NO. 2866
TO BE ANSWERED ON 15th DECEMBER, 2021

IMPORT OF API

2866. SHRI ASADUDDIN OWAISI:

Will the Minister of **COMMERCE & INDUSTRY** (वाणिज्य एवं उद्योग मंत्री) be pleased to state:

- (a) whether the Government has imposed any restriction on import Activated Pharmaceutical Ingredient (API) from certain countries;
- (b) if so, the details of the countries on which such restrictions have been imposed and volumes of API that was being imported from them prior to such restriction;
- (c) the details of the quantity and nature of API being exported by India in the last three years;
- (d) whether the Government has taken steps to increase the production of API in India to prevent supply shock that was witnessed during the initial period of COVID-19; and
- (e) if so, the details thereof?

ANSWER

वाणिज्य एवं उद्योग मंत्रालय में राज्य मंत्री (श्रीमती अनुप्रिया पटेल)

THE MINISTER OF STATE IN THE MINISTRY OF COMMERCE AND INDUSTRY
(SMT. ANUPRIYA PATEL)

(a)&(b) : No country-wise restrictions have been imposed on import of Active Pharmaceutical Ingredients (API).

(c): APIs such as Diloxanide furoate, cimetidine, famotidine, heterocyclic compounds, other antibiotics and erythromycin and its derivatives, together account for approximately 50% share in the total value of India's API exports.

The details of API exports for the last three years are tabled below:

India's API Exports (in USD Millions)				
Category	2018-19	2019-20	2020-21	2021-22(April-Oct 2021)
API (Bulk Drugs & Drug Intermediates)	3895.38	3867.77	4405.36	2469.84

(d)&(e) : To increase the domestic production of Active Pharmaceutical Ingredients (APIs), Intermediates and Key Starting Materials (KSMs), and also to reduce India's dependency on other countries for critical inputs and bulk drugs in the long run, the Government has approved the following schemes :-

- i. Scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crores for next five years;
- ii. Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs and for domestic manufacturing of pharmaceuticals.
